Fortis Life diagnostic contract development and manufacturing services
 

« Previous article
CrAg® LFA for De...

28th April 2021  Content supplied by: MAT BioTech B.V.

Breakthrough Endotoxin and NEP Test for Life Changing Products


MAT BioTech has released a Monocyte Activation Test (MAT), which is now being employed by R&D and QC microbiology teams at the world’s largest pharmaceutical manufacturers, as the release or non-endotoxin pyrogen (NEP) risk assessment assay for their parenterals.

Among others, MAT BioTech’s offering delivers:

  • Successful testing of all parenteral pharmaceuticals, biologicals, and medical devices.
  • Market-leading assay sensitivity (LoD 0.004 EU/ml).
  • 2,500 vials per PBMC (Peripheral Blood Mononuclear Cell) batch.
  • Successful LER (Low-Endotoxin Recovery) effect curbing.
  • Worldwide GMP certified MAT services.

Contact MAT BioTech for a free consultation today.


    

Tags:


Date Published: 28th April 2021

Source article link: View


View full company details


« Previous article
CrAg® LFA for Detection